Novonix (NVNXF) Liabilities and Shareholders Equity (2020 - 2025)

Novonix has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $282.9 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 25.13% year-over-year to $282.9 million; the trailing twelve-month figure through Dec 2025 stood at $1.1 billion (up 6.49% YoY), and the FY2023 full-year result was $263.3 million, down 5.08% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $282.9 million, down from $326.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $326.9 million in Q2 2025, with the low at $156.2 million in Q2 2021.
• Historically, Liabilities and Shareholders Equity has averaged $268.9 million across 5 years, with a median of $279.2 million in 2022.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity surged 201.81% — and 2024, when it dropped 14.26%.
• Novonix's Liabilities and Shareholders Equity stood at $319.7 million in 2021, then retreated by 13.23% to $277.4 million in 2022, then retreated by 5.08% to $263.3 million in 2023, then decreased by 14.14% to $226.1 million in 2024, then increased by 25.13% to $282.9 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $282.9 million (Q4 2025), $326.9 million (Q2 2025), and $226.1 million (Q4 2024), per Business Quant data.